ORIGINAL RESEARCH ARTICLE. A. Mirici, M. Meral and M. Akgun. Abstract
|
|
- Arabella Houston
- 6 years ago
- Views:
Transcription
1 ORIGINAL RESEARCH ARTICLE Clin Drug Invest 2003; 23 (1): /03/ /$230.00/0 Adis International Limited. All rights reserved. Comparison of the Efficacy of Nebulised Budesonide with Parenteral Corticosteroids in the Treatment of Acute Exacerbations of Chronic Obstructive Pulmonary Disease A. Mirici, M. Meral and M. Akgun Chest Diseases Department, Faculty of Medicine, Atatürk University, Erzurum, Turkey Abstract Objective: To compare the efficacy and safety of nebulised budesonide and systemic corticosteroid in the treatment of acute exacerbations of chronic obstructive pulmonary disease (COPD). Design: Randomised, double-blind, placebo-controlled, parallel-group trial. Patients and interventions: A total of 40 patients who had moderate to severe acute exacerbations of COPD and required hospitalisation were enrolled in the study. The patients were randomised to receive either nebulised budesonide 8mg daily (n = 21) or systemic (intravenous) prednisolone 40mg daily (n = 19). Airway obstruction (peak expiratory flow rate [PEFR]) and gas exchange (arterial partial pressure of oxygen [PaO 2] and carbon dioxide [PaCO 2], ph and oxygen saturation [SaO 2]) were evaluated at, at 6, 24 and 48 hours, and at day 10. Results: There were no significant differences between groups at baseline. In both groups, differences were significant for PEFR, SaO 2 and PaO 2 (p < 0.001), but not for PaCO 2 and ph, in comparison with their baseline values. There were no significant differences between groups for all parameters (PEFR, PaO 2, PaCO 2, ph and SaO 2) at all time periods. No adverse events were recorded in either group. Conclusions: Our study suggests that nebulised budesonide may be an alternative to parenteral corticosteroids in the treatment of acute exacerbations of COPD. Chronic obstructive pulmonary disease (COPD) has a chronic and progressive course; however, admission of patients with COPD increases during acute exacerbations. Patients with COPD may experience acute exacerbations one to four times in a year. Periods of acute exacerbations are important because of increased morbidity and mortality and healthcare costs. [1] There are still unclear areas in the standard management of acute exacerbations of COPD, for instance on the use of corticosteroids. Corticosteroid use is recommended as an addition to bron-
2 56 Mirici et al. chodilator, oxygen and antibacterial treatment for moderate to severe acute exacerbations of COPD in patients treated on an inpatient basis. [2,3] However, there are few studies on corticosteroid use in nebulised form. The role of inflammation in the pathogenesis of COPD has been emphasised, and it has been demonstrated that in acute exacerbations of COPD there are changes in the characteristics of inflammation and increases in eosinophils similar to those in asthma. [2-5] It has been known for a long time that corticosteroids are effective in asthma in both the stable and acute exacerbation phases. [6,7] In stable COPD, use of inhaled or systemic corticosteroids does not provide as dramatic benefits as in asthma. [8,9] There are a lot of studies about the usefulness of systemic corticosteroids in acute exacerbations of COPD, [10] but the dose and duration of the treatment are still uncertain. [11] The results of studies with high-dose nebulised corticosteroids in acute exacerbations of asthma are similar to those with systemic corticosteroids. [12,13] Use of nebulised corticosteroids in the treatment of acute exacerbations of COPD seems reasonable, because both diseases have inflammatory characteristics in the acute exacerbation periods. Additionally, the possible adverse effects of systemic corticosteroid treatment may be more problematic in elderly patients with COPD than in those with asthma. This study was conducted to compare the efficacy and safety of nebulised budesonide with systemic corticosteroid in the treatment of acute exacerbations of COPD. Patients and Methods Patients Patients with COPD admitted to the emergency department of our hospital for increased symptoms and requiring hospitalisation were included in the study. For all patients, the diagnosis of COPD was established as defined by the American Thoracic Society (ATS), and all of them had previously been followed up at the outpatient clinic. Thus none of them had postbronchodilator reversibility. Patients were classified as having had a mild, moderate or severe attack according to their clinical status. [1] Patients were included in the study if they had moderate to severe acute attacks of COPD. Exclusion criteria were exposure to systemic corticosteroids in the preceding month; presence of asthma, allergic rhinitis, atopy or any systemic disease (such as diabetes mellitus or hypertension); and being at risk of acute respiratory failure requiring mechanical ventilation. The study protocol was approved by the local ethics committee at the Research Hospital of the Faculty of Medicine. Patients provided written informed consent after baseline evaluation. Study Design The study was designed as a randomised, double-blind, parallel trial. The efficacy of the study medications was assessed from the beginning of the study to the tenth day. Follow-up times were utes, 6, 24 and 48 hours, and 10 days. The safety of the patients was monitored during treatment by investigators and consultant specialists. Patients were withdrawn from the study if acute respiratory acidosis or a need for mechanical ventilation occurred; these patients received appropriate treatment. Randomisation was performed using unmarked, ordered, sealed envelopes. No stratification method was used for randomisation. The randomisation order was determined using a computer-generated list of random numbers. Treatment Eligible patients who had moderate or severe acute attacks were randomly allocated to one of the two treatment groups: parenteral corticosteroid (PS) or nebulised corticosteroid (NS). Treatment in the consisted of prednisolone 40mg (intravenous ampoule) and a placebo nebulised suspension (placebo Respules 1 ); treatment in the consisted of nebulised budesonide sus- 1 Use of tradenames is for product identification only and does not imply endorsement.
3 Nebulised Corticosteroids in COPD 57 pension (Pulmicort Respules/Nebuampul 0.5 mg/ml; Astra-Zeneca Pharmaceutical Production) and an intravenous placebo (intravenous saline) for 10 days. Budesonide and placebo Respules were given as 4mg twice daily; prednisolone and placebo were given once daily intravenously. All medications and placebo were identical. Nebulisation procedures were performed by jet nebuliser (Porta Neb Ventstream 1803; Medic- Aid) with 80% of output of less than 5µm. Patients received standard treatment with a nebulised β- agonist (salbutamol 3.01mg) and anticholinergic (ipratropium bromide 0.5mg) combination every 6 hours, intravenous aminophylline (0.5 mg/kg/h) and oral or intravenous antibacterials at the discretion of the admitting physician. Supplementary oxygen therapy was used to maintain oxygen saturation (SaO 2 ) >90%. Measurements and Assessments All patients were hospitalised after baseline evaluations, which consisted of measurements of peak expiratory flow rate (PEFR) and/or forced expiratory volume in 1 second (FEV 1 ) and arterial blood gas analysis. PEFR measurements were carried out by Wright PEF meter. All patients exhaled three times and the highest value was recorded as the baseline value. Spirometry was carried out by computerised spirometer (Sensor Medics, Vmax22). However, this procedure could not be applied to all patients due to the physical restrictions of our clinic (the procedure is not available in our inpatient clinic, and there is a considerable distance between the in- and outpatient clinics). PEFR measurements were done according to a similar design at all time periods. Arterial blood samples were taken at baseline and during the study at 30 minutes, 6, 24 and 48 hours and day 10 for measurement of arterial partial pressure of oxygen (PaO 2 ) and carbon dioxide (PaCO 2 ), SaO 2 and ph. Patients were on room air at baseline and on day 10, but on supplementary oxygen at utes and 6, 24 and 48 hours. Statistical Analysis Pearson s chi-square test and the Mann-Whitney test were used to compare baseline values between groups. For comparison of changes in parameters between and in groups, the repeated measures analysis of variance test was used. For evaluation of variations in each step of assessment in relation to baseline values, the Mann-Whitney test was used. The data were analysed using SPSS version 9.0 (SPSS Inc.). The mean values of all steps and 95% CIs in each group were calculated. A p-value of <0.05 was considered significant. Results A total of 44 patients were randomised, from which 22 were randomly assigned to the and 22 to the. Four patients were withdrawn from the study for the following reasons: required mechanical ventilation (n = 1, ), pneumothorax (n = 1, ) and asked to be discharged from hospital (n = 2, ). Twenty-one of 40 patients who completed the study were administered parenteral treatment and 19 of them were administered nebulised treatment. Demographic characteristics and baseline values of the groups are summarised in table I. values of the groups were not significantly different (p > 0.05). In each group, it was found that increases in PEFR, PaO 2 and SaO 2 values within the groups were statistically significant (p < for all parameters). Changes in ph and PaCO 2 values in each Table I. Comparison of baseline characteristics of the two groups Characteristic p-value Age (y) Sex (F/M) 5/16 6/ PEFR (%) PaO 2 (mm Hg) PaCO 2 (mm Hg) SaO 2 (%) ph NS = nebulised corticosteroid group; PaCO 2 = arterial partial pressure of carbon dioxide; PaO 2 = arterial partial pressure of oxygen; PEFR = peak expiratory flow rate; PS = parenteral corticosteroid group; SaO 2 = arterial oxygen saturation.
4 58 Mirici et al. Table II. Mean values in the groups at different follow-up times Parameter PEFR (%) PS NS PaO 2 (mm Hg) PS NS PaCO 2 (mm Hg) PS NS SaO 2 (mm Hg) PS NS ph PS NS NS = nebulised corticosteroid group; PaCO 2 = arterial partial pressure of carbon dioxide; PaO 2 = arterial partial pressure of oxygen; PEFR = peak expiratory flow rate; PS = parenteral corticosteroid group; SaO 2 = arterial oxygen saturation. group were not statistically significant (p > 0.05). Average values for all parameters during the study are summarised in table II. In a comparison between the groups, it was found that there were no significant differences between percentage changes in PEFR, PaO 2 and 100 PaO 2 (mm Hg) PEFR (%) Fig. 2. Arterial partial pressure of oxygen (PaO 2): mean values, 95% CIs, minimum and maximum values (whiskers) for the two groups (nebulised corticosteroid [NS] and parenteral corticosteroid [PS]). In a comparison between groups, the differences in percentage change versus baseline values were not significant (p = 0.87, p = 0.32, p = 0.34, p = 0.09 and p = 0.15 at 30 minutes, 6 hours, 24 hours, 48 hours and 10 days, respectively). Fig. 1. Peak expiratory flow rate (PEFR): mean values, 95% CIs, minimum and maximum values (whiskers) for the two groups (nebulised corticosteroid [NS] and parenteral corticosteroid [PS]). In a comparison between groups, the differences in percentage change versus baseline values were not significant (p = 0.98, p = 0.43, p = 0.30, p = 0.83 and p = 0.36 at utes, 6 hours, 24 hours, 48 hours and 10 days, respectively). SaO 2 values during the entire period of assessment (p = 0.75, p = 1.00 and p = 1.00 for PEFR, PaO 2 and SaO 2, respectively) [figure 1, figure 2 and figure 3].
5 Nebulised Corticosteroids in COPD 59 SaO 2 (%) Fig. 3. Arterial oxygen saturation (SaO 2): mean values, 95% CIs, minimum and maximum values (whiskers) for the two groups (nebulised corticosteroid [NS] and parenteral corticosteroid [PS]). In a comparison between groups, the percentage changes versus baseline values were not significant (p = 0.70, p = 0.24, p = 0.12, p = 0.08 and p = 0.31 at utes, 6 hours, 24 hours, 48 hours and 10 days, respectively). For PaCO 2, there was a decrease in PaCO 2 in the by 4.8% compared with baseline, starting at day 2 and continuing to day 10. However, this difference was not statistically significant (figure 4). Similarly, there were changes in ph values compared with baseline of 3.27% in the PS group and 0.1% in the. This difference was also not statistically significant (p = 0.81) [figure 5]. No adverse effects were experienced in either group. Discussion In our study, it was determined that the effects of parenteral and nebulised corticosteroids were similar both on airway function and on arterial blood gas values. It has been demonstrated that there is inflammation in exacerbations of COPD similar to that in asthma. The increase in number and function of eosinophils is particularly important. [14] Viral infections have been suggested as being responsible PaCO 2 (mm Hg) ph Fig. 4. Arterial partial pressure of carbon dioxide (PaCO 2): mean values, 95% CIs, minimum and maximum values (whiskers) for the two groups (nebulised corticosteroid [NS] and parenteral corticosteroid [PS]). In a comparison between groups, the differences in percentage change versus baseline values were not significant (p = 0.34, p = 0.75, p = 0.67, p = 0.14 and p = 0.15 at utes, 6 hours, 24 hours, 48 hours and 10 days, respectively) min 30min Fig. 5. Arterial ph: mean values, 95% CIs, minimum and maximum values (whiskers) for the two groups (nebulised corticosteroid [NS] and parenteral corticosteroid [PS]). In a comparison between groups, the differences in percentage change versus baseline values were not significant (p = 0.06, p = 0.33, p = 0.95, p = 0.08 and p = 0.25 at,,, and at 10 days, respectively).
6 60 Mirici et al. for the increase in eosinophils in acute exacerbations. [15] Parenteral corticosteroids have been used in acute exacerbations of COPD for a long time. [10] Their use is also recommended in the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines as an additional treatment to that with bronchodilators, antibacterials and oxygen. [2] Systemic corticosteroid use in elderly patients with COPD may cause adverse reactions, which may be life-threatening. Although most guidelines recommend oral corticosteroid use in acute axacerbations of COPD, we used intravenous corticosteroids in order to obtain an identical treatment regimen for all patients as some patients were unable to have oral intake or had no possibility of being supplied with an oral drug. In recent years, use of nebulised corticosteroids in both children and adults with acute attacks of asthma has been investigated. [12,13] As nebulised corticosteroids are useful in both stable and acute periods of asthma, they may also be useful in acute exacerbations of COPD. They were found to be effective in a study using nebulised budesonide 2 mg/ml, but a differential diagnosis of patients could not be carried out due to a lack of information about bronchial hyperreactivity of patients before the attack. There are no further studies comparing the effectiveness of nebulised and systemic corticosteroids in acute exacerbations of COPD. In a randomised controlled trial by Morice et al., [16] it was demonstrated that over the 5 days of the study, the FEV 1 increases compared with baseline values between the groups were almost similar, but the biochemical markers associated with corticosteroid adverse effects were better with the nebulised budesonide group than with the corticosteroid group. Similarly, Maltais et al. [17] found that nebulised budesonide had the same effect as oral corticosteroid in the first 72 hours of an acute exacerbation of COPD. In that study, the assessed parameters were change in FEV 1 before and after bronchodilator therapy, dyspnoea score, arterial blood gases, duration of hospitalisation and adverse events. The changes in PaO 2 and PaCO 2 in the first 72 hours were significant only in the prednisolone group. In our study, PEFR measurement was used for assessment of airway obstruction. It is known that the correlation between FEV 1 and PEFR is not good, but PEFR was used for screening the change in values for patients in our study. All cases had a prior diagnosis of COPD spirometrically. In our study, percentage PEFR values were increased in both the NS and s. Similarly, increases in PaO 2 and SaO 2 values were also seen in both groups. However, there was no significant difference between the groups, which differs from the study by Maltais et al. [17] In our study, PaCO 2 and ph values were significantly different from baseline values in both groups, but the changes between the groups were not different. Maltais et al. in their study found that in the prednisolone group, the proportion of patients showing a substantial decrease in PaCO 2 (i.e. 5mm Hg) was significantly larger than in the budesonide or placebo groups. For these reasons, improvement in airway obstruction was similar to that study but the results of blood gas analysis were different from that study. Airway inflammation is an important component of increased airway obstruction. Thus, antiinflammatory treatment seems rational. However, a series of changes affecting the mechanics of breathing and gas exchange occur along with inflammation in acute exacerbations of COPD. [15,18-21] Dynamic hyperinflation and ventilation/perfusion mismatches are also important problems. There is evidence that use of parenteral corticosteroids during attacks decreases airflow resistance and dynamic hyperinflation. However, it is difficult to believe that these outcomes result only from an anti-inflammatory effect. It is possible that the entry of corticosteroids into the bloodstream may affect other tissues as well as the airway mucosa. However, with long-term systemic corticosteroid use, adverse effects on muscles are revealed, and early withdrawal results in recurrences of attacks. [22] This study is the one of the first to compare the efficacy of nebulised corticosteroids with that of
7 Nebulised Corticosteroids in COPD 61 systemic corticosteroids in acute exacerbations of COPD. Efficacy on airway obstruction was found to be similar to that with systemic corticosteroids. However, the observation of a trend to greater efficacy of systemic corticosteroids on arterial blood gas content is interesting. This may result from effects of corticosteroids on other mechanisms involved in gas exchange. The changes in parameters of gas exchange with nebulised budesonide are attributable to its anti-inflammatory effects of decreasing obstruction and decreasing airway resistance, either directly or indirectly. Improvement in airway obstruction would contribute to disappearance of early closing and dynamic hyperinflation. However, the similarity of these effects with nebulised corticosteroids to those with systemic corticosteroids is unclear. Conclusion This study showed that nebulised corticosteroids had similar efficacy to systemic corticosteroids in the treatment of acute exacerbations of COPD. In acute attacks, a nebulised form of corticosteroids is preferable to a systemic form because of fewer adverse effects. However, the effects of nebulised corticosteroids on gas exchange are not clearly understood. These effects may be indirect, since effects on airway inflammation alone cannot be responsible for all events occurring in acute attacks. The effects on gas exchange may be more important in acute attacks, especially for hypercapnoeic attacks. In order to establish the safe use of nebulised corticosteroids in both normocapnoeic and hypercapnoeic exacerbations of COPD, randomised trials in larger groups are needed. Acknowledgements The authors have provided no information on sources of funding or on conflicts of interest directly relevant to the content of this study. References 1. Turkish Thoracic Society -COPD Study Group. The national guidelines to diagnosis and treatment of chronic obstructive pulmonary disease [in Turkish]. Toraks Dergisi 2000; 1 Suppl. 2: National Heart, Lung, and Blood Institute. Global initiative for chronic obstructive lung disease. NHLBI Workshop Report 2701; 2001 Apr, Chapter 4 3. ATS Statement. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995; 152: Jeffery PK. Pathology of asthma and COPD. Eur Respir Rev 1997; 7 (43): Fabbri LM, Durham S, Holgate ST, et al. Assessment of airway inflammation: an overview. Eur Respir J Suppl 1998 Mar; 26: 6S-8S 6. National Heart, Lung, and Blood Institute. Global Initiative for Asthma. NHLBI/WHO Workshop Report NIH Publication No: Available from URL: http//www. ginasthma.com/ [Accessed 2002 Jun 10] 7. Turkish Thoracic Society - Asthma Study Group. The national guideline of diagnosis and treatment of asthma [in Turkish]. Toraks Dergisi 2000; 1 Suppl. 1: Mirici A, Bektas Y, Ozbakis G, et al. Effect of inhaled corticosteroids on respiratory function tests and airway inflammation in stable chronic obstructive pulmonary disease. Clin Drug Invest 2001; 21 (12): Posthma DS, Kerstjens HAM. Are inhaled glucocorticosteroids effective in chronic obstructive pulmonary disease? Am J Respir Crit Care Med 1999; 160: Niewoehner D, Erbland ML, Deupree RH, et al. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. N Engl J Med 1999; 340: Sayiner A, Aytemur ZA, Cirit M, et al. Systemic glucocorticosteroids in severe exacerbations of COPD. Chest 2001; 119: Westbroek J, Saarelainen S, Laher M, et al. Oral steroid-sparing effect of two doses of nebulized fluticasone propionate and placebo in patients with severe chronic asthma. Respir Med 1999; 93: Winter JH, Dhillon BP, Winter JE, et al. Effect of the early substitution of nebulized fluticasone proprionate 2mg bid for oral prednisolone 50mg in adults during the early recovery period of an acute exacerbation. Eur Respir J 1997; 25 (Suppl): 174s 14. Saetta M. Airway pathology of COPD compared with asthma. Eur Respir Rev 1997; 7 (45): Calverley PMA, Rennard S, Agusti AGN, et al. Current and future management of acute exacerbations of chronic obstructive pulmonary disease. Eur Respir Rev 1999; 9 (67): Morice AH, Morris D, Lawson-Matthew P. A comparison of nebulized budesonide with oral prednisolone in the treatment of exacerbations of obstructive pulmonary disease. Clin Pharmacol Ther 1996 Dec; 60 (6): Maltais F, Ostinelli J, Bourbeau J, et al. Comparison of nebulized budesonide and oral prednisolone with placebo in the treatment of acute exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Am J Respir Crit Care Med 2002 Mar 1; 165 (5): Albert RK, Martin TR, Lewis SW. Controlled clinical trial of methylprednisolone in patients with chronic bronchitis and acute respiratory failure. Ann Intern Med 1980; 92: 753-8
8 62 Mirici et al. 19. Thompson WH, Nielson CP, Carvalbo P, et al. Controlled trial of oral prednisolone in outpatients with COPD exacerbation. Am J Respir Crit Care Med 1996l 154: Murata GH, Gorby MS, Chick TW. Intravenous and oral corticosteroids for the prevention of relapse after treatment of decompensated COPD: effects on patients with a history of multiple relapses. Chest 2000; 98: Rubini F, Rampulla C, Nava S. Acute effect of corticosteroids on respiratory mechanics in mechanically ventilated patients with chronic airflow obstruction and acute respiratory failure. Am J Respir Crit Care Med 1994; 149: Decramer M, Stas K. Corticosteroid-induced myopathy involving respiratory muscles in patients with COPD and asthma. Am Rev Respir Dis 1992; 146: Correspondence and offprints: Dr M. Akgun, Atatürk Universitesi, Aziziye Arastirma Hastanesi, Gogus Hastaliklari, Yenisehir Girisi, Erzurum, Turkey. dr_metinakgun@yahoo.com
H ospitalisation due to an exacerbation of chronic
713 CHRONIC OBSTRUCTIVE PULMONARY DISEASE Intravenous aminophylline in patients admitted to hospital with non-acidotic exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled
More informationSupplementary Medications during asthma attack. Prof. Dr Finn Rasmussen PhD. DrMedSc. Near East University Hospital North Cyprus
Supplementary Medications during asthma attack Prof. Dr Finn Rasmussen PhD. DrMedSc. Near East University Hospital North Cyprus Conflicts of Interest None Definition of Asthma Airway narrowing that is
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationTORCH: Salmeterol and Fluticasone Propionate and Survival in COPD
TORCH: and Propionate and Survival in COPD April 19, 2007 Justin Lee Pharmacy Resident University Health Network Outline Overview of COPD Pathophysiology Pharmacological Treatment Overview of the TORCH
More informationChronic Obstructive Pulmonary Disease (COPD) Clinical Guideline
Chronic Obstructive Pulmonary Disease (COPD) Clinical These clinical guidelines are designed to assist clinicians by providing an analytical framework for the evaluation and treatment of patients. They
More informationEfficacy of Nebulised Ipratropium in Acute Bronchial Asthma
ORIGINAL ARTICLE JIACM 2002; 3(4): 353-59 Efficacy of Nebulised Ipratropium in Acute Bronchial Asthma Praveen Aggarwal*, Onkar Singh**, Jyoti P Wali***, Rohini Handa*, Sada N Dwivedi****, Ashutosh Biswas*****,
More informationBasic mechanisms disturbing lung function and gas exchange
Basic mechanisms disturbing lung function and gas exchange Blagoi Marinov, MD, PhD Pathophysiology Department, Medical University of Plovdiv Respiratory system 1 Control of breathing Structure of the lungs
More informationTHE ROLE OF NEBULIZED BUDESONIDE IN THE TREATMENT OF EXACERBATIONS OF COPD
ERJ Express. Published on January 24, 2007 as doi: 10.1183/09031936.00073506 THE ROLE OF NEBULIZED BUDESONIDE IN THE TREATMENT OF EXACERBATIONS OF COPD Hakan GUNEN, MD, Associate Professor* Suleyman Savas
More informationStep-down approach in chronic stable asthma: A comparison of reducing dose Inhaled Formoterol/ Budesonide with maintaining Inhaled Budesonide.
Step-down approach in chronic stable asthma: A comparison of reducing dose Inhaled Formoterol/ Budesonide with maintaining Inhaled Budesonide. By: DR MOHD SHAMSUL AMRI Supervisor: Associate Professor Dr
More informationEffect of formoterol/budesonide combination on arterial blood gases in patients with acute exacerbation of COPD
Respiratory Medicine (2006) 100, 212 217 Effect of formoterol/budesonide combination on arterial blood gases in patients with acute exacerbation of COPD M. Cazzola a,, P. Noschese a, F. De Michele b, G.
More informationOn completion of this chapter you should be able to: discuss the stepwise approach to the pharmacological management of asthma in children
7 Asthma Asthma is a common disease in children and its incidence has been increasing in recent years. Between 10-15% of children have been diagnosed with asthma. It is therefore a condition that pharmacists
More informationExacerbations. Ronald Dahl, Aarhus University Hospital, Denmark
1st WAO Allied Health Session - Asthma: Diagnosi Exacerbations Ronald Dahl, Aarhus University Hospital, Denmark The health professional that care for patients with asthma exacerbation must be able to Identificafy
More informationExacerbations of COPD. Dr J Cullen
Exacerbations of COPD Dr J Cullen Definition An AECOPD is a sustained worsening of the patient s clinical condition from their stable state that is beyond their usual day-to-day variation is acute in onset
More informationLecture Notes. Chapter 3: Asthma
Lecture Notes Chapter 3: Asthma Objectives Define asthma and status asthmaticus List the potential causes of asthma attacks Describe the effect of asthma attacks on lung function List the clinical features
More informationDATE: 09 December 2009 CONTEXT AND POLICY ISSUES:
TITLE: Tiotropium Compared with Ipratropium for Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease: A Review of the Clinical Effectiveness DATE: 09 December 2009 CONTEXT AND POLICY
More informationManagement of Acute Exacerbations
15 Management of Acute Exacerbations Cenk Kirakli Izmir Dr. Suat Seren Chest Diseases and Surgery Training Hospital Turkey 1. Introduction American Thoracic Society (ATS) and European Respiratory Society
More informationChoosing an inhaler for COPD made simple. Dr Simon Hart Castle Hill Hospital
Choosing an inhaler for COPD made simple Dr Simon Hart Castle Hill Hospital 1 Declaration of interests I have received speaker fees, sponsorship to attend conferences, and funding for research from companies
More informationChronic obstructive pulmonary disease (COPD) is characterized
DANIEL E. HILLEMAN, PharmD ABSTRACT OBJECTIVE: To review the role of long-acting bronchodilators in the treatment of chronic obstructive pulmonary disease (COPD), including the importance of treatment
More informationTreatment Responses. Ronald Dahl, Aarhus University Hospital, Denmark
Asthma and COPD: Are They a Spectrum Treatment Responses Ronald Dahl, Aarhus University Hospital, Denmark Pharmacological Treatments Bronchodilators Inhaled short-acting β -Agonist (rescue) Inhaled short-acting
More informationStudy No.: Title: Rationale: Phase: Study Period Study Design: Centres: Indication: Treatment: Objectives : Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationOptimum COPD Care in 2010 Why Not Now? David E. Taylor, M.D. Pulmonary/Critical Care Ochnser Medical Center
Optimum COPD Care in 2010 Why Not Now? David E. Taylor, M.D. Pulmonary/Critical Care Ochnser Medical Center dtaylor@ochsner.org Observations from Yesterday EPIC is epidemic No EMR No Way!!! Accountability/Benchmarking
More informationรศ. นพ. ว ชรา บ ญสว สด M.D., Ph.D. ภาคว ชาอาย รศาสตร คณะแพทยศาสตร มหาว ทยาล ยขอนแก น
รศ. นพ. ว ชรา บ ญสว สด M.D., Ph.D. ภาคว ชาอาย รศาสตร คณะแพทยศาสตร มหาว ทยาล ยขอนแก น COPD Guideline Changing concept in COPD management Evidences that we can offer COPD patients better life COPD Guidelines
More informationASTHMA. Epidemiology. Pathophysiology. Diagnosis. IAP UG Teaching slides
BRONCHIAL ASTHMA ASTHMA Epidemiology Pathophysiology Diagnosis 2 CHILDHOOD ASTHMA Childhood bronchial asthma is characterized by Airway obstruction which is reversible Airway inflammation Airway hyper
More informationThis is a cross-sectional analysis of the National Health and Nutrition Examination
SUPPLEMENTAL METHODS Study Design and Setting This is a cross-sectional analysis of the National Health and Nutrition Examination Survey (NHANES) data 2007-2008, 2009-2010, and 2011-2012. The NHANES is
More informationRapid Effects of Inhaled Corticosteroids in Acute Asthma Gustavo J. Rodrigo, MD.
Rapid Effects of Inhaled Corticosteroids in Acute Asthma Gustavo J. Rodrigo, MD WWW.chestjournal.org Background: Current reviews on the use of inhaled corticosteroids (ICS) for acute asthma underestimated
More informationSecondary Outcome/Efficacy Variable(s):
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationTips on managing asthma in children
Tips on managing asthma in children Dr Ranjan Suri Consultant in Respiratory Paediatrics Bupa Cromwell Hospital Clinics: Friday (pm) Asthma in Children Making the diagnosis Patterns of childhood asthma
More informationADULT ASTHMA GUIDE SUMMARY. This summary provides busy health professionals with key guidance for assessing and treating adult asthma.
ADULT ASTHMA GUIDE SUMMARY This summary provides busy health professionals with key guidance for assessing and treating adult asthma. Its source document Asthma and Respiratory Foundation NZ Adult Asthma
More informationKnowledge and Practice of Medical Doctors on Chronic Obstructive Pulmonary Disease: A Preliminary Survey from a State Hospital
ORIGINAL ARTICLE Knowledge and Practice of Medical Doctors on Chronic Obstructive Pulmonary Disease: A Preliminary Survey from a State Hospital ARM Fauzi, MRCP Kulliyah of Medicine, International Islamic
More informationCOPD/ Asthma. Dr Heather Lewis Honorary Clinical Lecturer
COPD/ Asthma Dr Heather Lewis Honorary Clinical Lecturer Objectives To understand the pathogenesis of asthma/ COPD To recognise the clinical features of asthma/ COPD To know how to diagnose asthma/ COPD
More informationAn Audit on Hospital Management of Bronchial Asthma
An Audit on Hospital Management of Bronchial Asthma Pages with reference to book, From 298 To 300 Javaid A. Khan, Shehryar Saghir, Ghazala Tabassum, S. Fayyaz Husain ( Department of Medicine, The Aga Khan
More informationThe FDA Critical Path Initiative
The FDA Critical Path Initiative Clinical Considerations for Demonstration of Dose-response for Inhaled Corticosteroids - Exhaled Nitric Oxide Model Badrul A. Chowdhury, MD, PhD Director Division of Pulmonary
More informationAsthma is global health problem in children,
Paediatrica Indonesiana VOLUME 52 July NUMBER 4 Original Article Efficacy of salbutamol-ipratropium bromide nebulization compared to salbutamol alone in children with mild to moderate asthma attacks Matahari
More informationCOPD: A Renewed Focus. Disclosures
COPD: A Renewed Focus Heath Latham, MD Assistant Professor Division of Pulmonary and Critical Care Medicine Disclosures No Business Interests No Consulting No Speakers Bureau No Off Label Use to Discuss
More informationOver the last several years various national and
Recommendations for the Management of COPD* Gary T. Ferguson, MD, FCCP Three sets of guidelines for the management of COPD that are widely recognized (from the European Respiratory Society [ERS], American
More informationDefining COPD. Georgina Grantham Community Respiratory Team Leader/ Respiratory Nurse Specialist
Defining COPD Georgina Grantham Community Respiratory Team Leader/ Respiratory Nurse Specialist Defining COPD Chronic Obstructive Pulmonary Disease (COPD) is a common, preventable and treatable disease
More informationMedicine Dr. Kawa Lecture 4 - Treatment of asthma :
Medicine Dr. Kawa Lecture 4 - Treatment of asthma : Avoiding allergens. Hyposensitization :Subcutaneous injections of inially very small, but gradually increasing doses of allergens (desensitization or
More informationThey are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:
bring together everything NICE says on a topic in an interactive flowchart. are interactive and designed to be used online. They are updated regularly as new NICE guidance is published. To view the latest
More informationDecramer 2014 a &b [21]
Buhl 2015 [19] Celli 2014 [20] Decramer 2014 a &b [21] D Urzo 2014 [22] Maleki-Yazdi 2014 [23] Inclusion criteria: Diagnosis of chronic obstructive pulmonary disease; 40 years of age or older; Relatively
More informationTreatment. Assessing the outcome of interventions Traditionally, the effects of interventions have been assessed by measuring changes in the FEV 1
58 COPD 59 The treatment of COPD includes drug therapy, surgery, exercise and counselling/psychological support. When managing COPD patients, it is particularly important to evaluate the social and family
More informationType of intervention Treatment. Economic study type Cost-effectiveness analysis.
Cost-effectiveness of salmeterol/fluticasone propionate combination product 50/250 micro g twice daily and budesonide 800 micro g twice daily in the treatment of adults and adolescents with asthma Lundback
More informationSupplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Calverley P M A, Anzueto A R, Carter K, et
More informationLife-long asthma and its relationship to COPD. Stephen T Holgate School of Medicine University of Southampton
Life-long asthma and its relationship to COPD Stephen T Holgate School of Medicine University of Southampton Definitions COPD is a preventable and treatable disease with some significant extrapulmonary
More informationThe New England Journal of Medicine. Clinical Practice. Overview. Oxygen
Clinical Practice This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various strategies is then presented, followed by a review of formal guidelines,
More informationDiagnosis, Treatment and Management of Asthma
Diagnosis, Treatment and Management of Asthma Asthma is a complex disorder characterized by variable and recurring symptoms, airflow obstruction, bronchial hyperresponsiveness, and an underlying inflammation.
More informationCOPD is a syndrome of chronic limitation in expiratory airflow encompassing emphysema or chronic bronchitis.
1 Definition of COPD: COPD is a syndrome of chronic limitation in expiratory airflow encompassing emphysema or chronic bronchitis. Airflow obstruction may be accompanied by airway hyper-responsiveness
More information2/12/2015. ASTHMA & COPD The Yin &Yang. Asthma General Information. Asthma General Information
ASTHMA & COPD The Yin &Yang Arizona State Association of Physician Assistants March 6, 2015 Sedona, Arizona Randy D. Danielsen, PhD, PA-C, DFAAPA Dean & Professor A.T. Still University Asthma General Information
More informationDisclosure and Conflict of Interest 8/15/2017. Pharmacist Objectives. At the conclusion of this program, the pharmacist will be able to:
Digging for GOLD Rebecca Young, PharmD, BCACP, Roosevelt University College of Pharmacy Assistant Professor of Clinical Sciences Practice Site Advocate Medical Group-Nesset Pavilion Disclosure and Conflict
More informationLecture Notes. Chapter 4: Chronic Obstructive Pulmonary Disease (COPD)
Lecture Notes Chapter 4: Chronic Obstructive Pulmonary Disease (COPD) Objectives Define COPD Estimate incidence of COPD in the US Define factors associated with onset of COPD Describe the clinical features
More informationAdmissions to hospital with exacerbations of chronic obstructive pulmonary disease: effect of age related factors and service organisation
843 CHRONIC OBSTRUCTIVE PULMONARY DISEASE Admissions to hospital with exacerbations of chronic obstructive pulmonary disease: effect of age related factors and service organisation M J Connolly, D Lowe,
More informationChronic Obstructive Pulmonary Disease (COPD) Measures Document
Chronic Obstructive Pulmonary Disease (COPD) Measures Document COPD Version: 3 - covering patients discharged between 01/10/2017 and present. Programme Lead: Jo Higgins Clinical Lead: Dr Paul Albert Number
More informationProf Neil Barnes. Respiratory and General Medicine London Chest Hospital and The Royal London Hospital
Prof Neil Barnes Respiratory and General Medicine London Chest Hospital and The Royal London Hospital ASTHMA: WHEN EVERYTHING FAILS WHAT DO YOU DO? South GP CME 2013, Dunedin Saturday 17 th August 2013
More informationTurning Science into Real Life Roflumilast in Clinical Practice. Roland Buhl Pulmonary Department Mainz University Hospital
Turning Science into Real Life Roflumilast in Clinical Practice Roland Buhl Pulmonary Department Mainz University Hospital Therapy at each stage of COPD I: Mild II: Moderate III: Severe IV: Very severe
More informationRoflumilast (Daxas) for chronic obstructive pulmonary disease
Roflumilast (Daxas) for chronic obstructive pulmonary disease August 2009 This technology summary is based on information available at the time of research and a limited literature search. It is not intended
More informationAbstract Background Theophylline is widely used in the treatment of asthma, and there is evidence that theophylline has antiinflammatory
Thorax 2000;55:837 841 837 National Heart and Lung Institute, Imperial College School of Medicine and Royal Brompton Hospital, London SW3 6LY, UK S Lim A Jatakanon K F Chung P J Barnes Napp Laboratories
More informationDual-Controller Asthma Therapy: Rationale and Clinical Benefits
B/1 Dual-Controller Asthma Therapy: Rationale and Clinical Benefits MODULE B The 1997 National Heart, Lung, and Blood Institute (NHLBI) Expert Panel guidelines on asthma management recommend a 4-step approach
More informationAsthma - Chronic. Presentations of asthma Cough Wheeze Breathlessness Chest tightness
Asthma - Chronic Definition of asthma Chronic inflammatory disease of the airways 3 components: o Reversible and variable airflow obstruction o Airway hyper-responsiveness to stimuli o Inflammation of
More informationCOPD Challenge CASE PRESENTATION
Chronic obstructive pulmonary disease (COPD) exacerbations may make up more than 10% of acute medical admissions [1], and they are increasingly recognised as a cause of significant morbidity and mortality
More informationWhat is the optimal treatment strategy for chronic obstructive pulmonary disease exacerbations?
Eur Respir J 2002; 19: 928 935 DOI: 10.1183/09031936.02.00268702 Printed in UK all rights reserved Copyright #ERS Journals Ltd 2002 European Respiratory Journal ISSN 0903-1936 What is the optimal treatment
More informationDifferential diagnosis
Differential diagnosis The onset of COPD is insidious. Pathological changes may begin years before symptoms appear. The major differential diagnosis is asthma, and in some cases, a clear distinction between
More informationThey are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:
bring together everything NICE says on a topic in an interactive flowchart. are interactive and designed to be used online. They are updated regularly as new NICE guidance is published. To view the latest
More informationC hronic obstructive pulmonary disease (COPD) is one of
589 RESPIRATORY INFECTIONS Time course of recovery of health status following an infective exacerbation of chronic bronchitis S Spencer, P W Jones for the GLOBE Study Group... Thorax 2003;58:589 593 See
More informationInternational Journal of Medical Research & Health Sciences
International Journal of Medical Research & Health Sciences www.ijmrhs.com Volume 2 Issue 3 July - Sep Coden: IJMRHS Copyright @2013 ISSN: 2319-5886 Received: 23 th May 2013 Revised: 24 th Jun 2013 Accepted:
More informationDirect and indirect CV effects of current drugs and those in development
Direct and indirect CV effects of current drugs and those in development Heribert Staudinger CSRC MARCH 201 Cardiac Manifestations of COPD Cardiovascular Disease is probably the most frequent and most
More informationComparison of the Effect of Short Course of Oral Prednisone in Patients with Acute Asthma
ISPUB.COM The Internet Journal of Pulmonary Medicine Volume 7 Number 1 Comparison of the Effect of Short Course of Oral Prednisone in Patients with Acute Asthma E Razi, G Moosavi Citation E Razi, G Moosavi.
More informationAECOPD: Management and Prevention
Neil MacIntyre MD Duke University Medical Center Durham NC Professor P.J. Barnes, MD, National Heart and Lung Institute, London UK Professor Peter J. Barnes, MD National Heart and Lung Institute, London
More informationAsthma training. Mike Levin Division of Asthma and Allergy Red Cross Hospital
Asthma training Mike Levin Division of Asthma and Allergy Red Cross Hospital Introduction Physiology Diagnosis Severity Treatment Control Stage 3 of guidelines Acute asthma Drug delivery Conclusion Overview
More informationResearch Review. Salmeterol/fluticasone propionate (Seretide ) in COPD. Extended listing for salmeterol/fluticasone propionate in COPD
Research Review Salmeterol/fluticasone propionate (Seretide ) in COPD Extended listing for salmeterol/fluticasone propionate in COPD In New Zealand, salmeterol/fluticasone propionate (SFC) (Seretide )
More informationRecurrent wheezing illnesses 24.9% Similar to Australia Above global averages
Prof Mike South Department of General Medicine Royal Children s Hospital Melbourne Australia www.mikesouth.org.au Asthma is very common in Australia Approx 25% children have recurrent wheezing illnesses
More informationGINA. At-A-Glance Asthma Management Reference. for adults, adolescents and children 6 11 years. Updated 2017
GINA At-A-Glance Asthma Management Reference for adults, adolescents and children 6 11 years Updated 2017 This resource should be used in conjunction with the Global Strategy for Asthma Management and
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis
More informationAsthma COPD Overlap (ACO)
Asthma COPD Overlap (ACO) Dr Thomas Brown Consultant Respiratory Physician Thomas.Brown@porthosp.nhs.uk Dr Hitasha Rupani Consultant Respiratory Physician Hitasha.rupani@porthosp.nhs.uk What is Asthma
More informationPotential risks of ICS use
Potential risks of ICS use Randomised controlled trial Observational study Systematic review Pneumonia Tuberculosis Bone fracture Skin thinning/easy bruising Cataract Diabetes No effect on fracture risk
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationGUIDE LINE SUMMARY THE DIAGNOSIS AND TREATMENT OF ADULT ASTHMA BEST PRACTICE EV I DENCE-BASED KEY MESSAGES. Diagnosis.
THE DIAGSIS AND TREATMENT OF ADULT ASTHMA The purpose of the guideline is to provide an evidence-based summary of the diagnostic management and treatment options available for asthma in the adult population
More informationRESPIRATORY CARE IN GENERAL PRACTICE
RESPIRATORY CARE IN GENERAL PRACTICE Definitions of Asthma and COPD Asthma is due to inflammation of the air passages in the lungs and affects the sensitivity of the nerve endings in the airways so they
More informationWhat s new in COPD? Apichart Khanichap MD. Department of Medicine, Faculty of Medicine, Thammasat university
What s new in COPD? Apichart Khanichap MD. Department of Medicine, Faculty of Medicine, Thammasat university Management stable COPD Relieve symptoms Improve exercise tolerance Improve health status Prevent
More informationASTHMA-COPD OVERLAP SYNDROME 2018: What s All the Fuss?
ASTHMA-COPD OVERLAP SYNDROME 2018: What s All the Fuss? Randall W. Brown, MD MPH AE-C Association of Asthma Educators Annual Conference July 20, 2018 Phoenix, Arizona FACULTY/DISCLOSURES Randall Brown,
More informationASTHMA & RESPIRATORY FOUNDATION NZ ADULT ASTHMA GUIDELINES: A QUICK REFERENCE GUIDE 1
ASTHMA & RESPIRATORY FOUNDATION NZ ADULT ASTHMA GUIDELINES: A QUICK REFERENCE GUIDE 1 1. Richard Beasley, Bob Hancox, Matire Harwood, Kyle Perrin, Betty Poot, Janine Pilcher, Jim Reid, Api Talemaitoga,
More informationResearch in Real Life
Research in Real Life Study 1: Exploratory study - identifying the benefits of pmdi versus Diskus for delivering fluticasone/salmeterol combination therapy in patients with chronic obstructive pulmonary
More informationDoes the multidimensional grading system (BODE) correspond to differences in health status of patients with COPD?
AUTHOR COPY ORIGINAL RESEARCH Does the multidimensional grading system (BODE) correspond to differences in health status of patients with COPD? Kian-Chung Ong 1 Suat-Jin Lu 1 Cindy Seok-Chin Soh 2 1 Department
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationChronic Obstructive Pulmonary Disease
Chronic Obstructive Pulmonary Disease 07 Contributor Dr David Tan Hsien Yung Definition, Diagnosis and Risk Factors for (COPD) Differential Diagnoses Goals of Management Management of COPD THERAPY AT EACH
More informationAsma, BPCO ed Esercizio Fisico Ferrara, 6 e 7 Novembre Overlap asma BPCO. Dr. Marco Contoli
Asma, BPCO ed Esercizio Fisico Ferrara, 6 e 7 Novembre 2015 Overlap asma BPCO Dr. Marco Contoli Sezione di Medicina Interna e Cardio-Respiratoria Dipartimento di Scienze Mediche Università di Ferrara (Sept.
More informationManagement of Acute Exacerbations of COPD
MiCMRC Educational Webinar Management of Acute Exacerbations of COPD August 22, 2018 MiCMRC Educational Webinar Management of Acute Exacerbations of COPD Expert Presenter: Catherine A. Meldrum PhD RN MS
More informationManagement of Acute Asthma Exacerbations in Children 2012 Update. Sharon Kling Dept Paediatrics & Child Health University of Stellenbosch
Management of Acute Asthma Exacerbations in Children 2012 Update Sharon Kling Dept Paediatrics & Child Health University of Stellenbosch Acknowledgements BTS/SIGN guidelines GINA guidelines NAEPP guidelines
More informationYou ve come a long way, baby.
COPD Dr Badri Paudel Dept of Medicine GMC/CHRC 4/22/12 badri@gmc 2 You ve come a long way, baby. Wayne McLaren Former Marlboro Man 4/22/12 badri@gmc 3 Age 30 a robust young man Age 51 riding into the sunset
More informationEvaluation of the Use of High-Dose Inhaled Corticosteroids for the Treatment of Acute Asthma
11 Inhaled Corticosteroids for Asthma Attacks ORIGINAL ARTICLE RAMR 2016;1:11-16 ISSN 1852-236X Evaluation of the Use of High-Dose Inhaled Corticosteroids for the Treatment of Acute Asthma Correspondence:
More informationMAYA RAMAGOPAL M.D. DIVISION OF PULMONOLOGY & CYSTIC FIBROSIS CENTER
MAYA RAMAGOPAL M.D. DIVISION OF PULMONOLOGY & CYSTIC FIBROSIS CENTER 16 year old female with h/o moderate persistent asthma presents to the ED after 6 hours of difficulty breathing, cough, and wheezing
More informationORIGINAL ARTICLE ABSTRACT SUMMARY AT A GLANCE INTRODUCTION
bs_bs_banner ORIGINAL ARTICLE Effects of nebulized high-dose budesonide on moderate-to-severe acute exacerbation of asthma in children: A randomized, double-blind, placebo-controlled study AI-HUAN CHEN,*
More informationIs there any correlation between the ATS, BTS, ERS and GOLD COPD s severity scales and the frequency of hospital admissions?
Respiratory Medicine (2004) 98, 178 183 Is there any correlation between the ATS, BTS, ERS and GOLD COPD s severity scales and the frequency of hospital admissions? Maria Tsoumakidou, Nikolaos Tzanakis,
More informationRespiratory Medicine. Some pet peeves and other random topics. Kyle Perrin
Respiratory Medicine Some pet peeves and other random topics Kyle Perrin Overview 1. Acute asthma Severity assessment and management 2. Acute COPD NIV and other management 3. Respiratory problems in the
More informationThe Relationship among COPD Severity, Inhaled Corticosteroid Use, and the Risk of Pneumonia.
The Relationship among COPD Severity, Inhaled Corticosteroid Use, and the Risk of Pneumonia. Rennard, Stephen I; Sin, Donald D; Tashkin, Donald P; Calverley, Peter M; Radner, Finn Published in: Annals
More informationBudesonide treatment of moderate and severe asthma in children: A doseresponse
Budesonide treatment of moderate and severe asthma in children: A doseresponse study Soren Pedersen, MD, PhD, and Ove Ramsgaard Hansen, MD Kolding, Denmark Objective: The purpose of the study was to evaluate
More informationThe Journal Club: COPD Exacerbations
252 The Journal Club: COPD Exacerbations Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation Journal Club The Journal Club: COPD Exacerbations Ron Balkissoon, MD, MSc, DIH, FRCPC 1 Abbreviations:
More informationCOPD. Breathing Made Easier
COPD Breathing Made Easier Catherine E. Cooke, PharmD, BCPS, PAHM Independent Consultant, PosiHleath Clinical Associate Professor, University of Maryland School of Pharmacy This program has been brought
More informationSHORT COMMUNICATION. Abstract. Kevin R. Murphy, 1 Tom Uryniak, 2 Ubaldo J. Martin 2 and James Zangrilli 2
SHORT COMMUNICATION Drugs R D 212; 12 (1): 9-14 1179-691/12/1-9 ª 212 Murphy et al., publisher and licensee Adis Data Information BV. This is an open access article published under the terms of the Creative
More informationAT TRIAGE. Alberta Acute Childhood Asthma Pathway: Evidence based* recommendations For Emergency / Urgent Care
1 1 Should the child be placed into the Pathway? Asthma Clinical Score (PRAM) Inclusion Children 1 year and 18 years of age who present with wheezing and respiratory distress, and have been diagnosed by
More informationPulmonary Function Testing: Concepts and Clinical Applications. Potential Conflict Of Interest. Objectives. Rationale: Why Test?
Pulmonary Function Testing: Concepts and Clinical Applications David M Systrom, MD Potential Conflict Of Interest Nothing to disclose pertinent to this presentation BRIGHAM AND WOMEN S HOSPITAL Harvard
More informationroflumilast 500 microgram tablets (Daxas ) SMC No. (635/10) Nycomed Ltd
roflumilast 500 microgram tablets (Daxas ) SMC No. (635/10) Nycomed Ltd 06 August 2010 (Issued 10 September 2010) The Scottish Medicines Consortium (SMC) has completed its assessment of the above product
More information